Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
12/2005
12/08/2005US20050272709 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death
12/08/2005US20050272649 Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
12/08/2005US20050272148 Method of collecting placental stem cells
12/08/2005US20050272077 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
12/08/2005US20050271743 Treatment of inflammatory skin conditions
12/08/2005US20050271723 Dosage forms for treatment of benign prostatic hyperplasia
12/08/2005US20050271717 Dry-granulated dosage forms of tablets or capsules; preparation by compressing the mixture, milling, grinding or sieving the compressed material; hypercholesterolemia, hyperlipidemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's disease
12/08/2005US20050271716 Preparation containing basic drug
12/08/2005CA2569081A1 Quinazoline derivative
12/07/2005EP1602660A1 Aminophosphonic acid derivatives, addition salts thereof and s1p receptor modulators
12/07/2005EP1602658A1 Tricyclic pyrazole derivatives as cannabinoid receptor antagonists
12/07/2005EP1602657A2 Substituted 9-alkyladenines
12/07/2005EP1602656A1 Pyrazole derivatives having affinity for cb1 and/or cb2 receptors
12/07/2005EP1602379A1 Botulinum toxin B for treating spastic muscle
12/07/2005EP1602370A2 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
12/07/2005EP1602369A2 Bupropion Metabolites and Methods of their Synthesis and Use
12/07/2005EP1601782A2 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b)
12/07/2005EP1601361A2 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
12/07/2005EP1525198B1 Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
12/07/2005EP1496917B1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
12/07/2005EP1379528A4 Pyrazolopyrimidines as therapeutic agents
12/07/2005EP1307449B1 1,4-dihydropyridines as bradykinin antagonists
12/07/2005EP1303269B1 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
12/07/2005EP1294711B1 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
12/07/2005EP1216257B1 Compounds for the treatment of ischemia
12/07/2005EP1216241B1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
12/07/2005EP1178812B1 Methods of making conditioned cell culture medium compositions
12/07/2005EP1147089B1 Phenylphenanthridines with pde-iv inhibiting activity
12/07/2005EP1124548B1 Compositions for the treatment and prevention of cardiovascular diseases
12/07/2005EP0794794B1 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
12/07/2005CN1705659A Large conductance calcium-activated k channel opener
12/07/2005CN1704404A Tricyclic protein kinase inhibitors
12/07/2005CN1704121A Anti-angiogenic compositions and methods of use
12/07/2005CN1230433C Cyclic AMP-specific phosphodiesterase inhibitors
12/07/2005CN1230423C 1,4-disubstituted piperazine derivatives useful as uro-selective dollar g(a)1-adrenoceptor blockers
12/07/2005CN1230418C Selective androgen receptor modulators and methods of use thereof
12/07/2005CN1230195C Oral preparation containing seaweed for reduction of plaque and calculus
12/07/2005CN1230193C Water-purging pill
12/07/2005CN1230178C Remedies for bladder irritation signs in association with prostatauxe
12/07/2005CN1230173C Preventives and remedies for complications of diabetes
12/07/2005CN1230166C Gyrase inhibitors and uses thereof
12/07/2005CN1230160C Application of bamboo leaf total flavone in medicine for treating and preventing prostate disease
12/06/2005US6972299 Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
12/06/2005US6972295 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis
12/06/2005US6972128 allogeneic immunotherapy; vaccines; immortalization
12/06/2005CA2349338C Novel macrolide antibiotics
12/01/2005WO2005112944A1 Drug for prevention or treatment of diabetes
12/01/2005US20050267304 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders
12/01/2005US20050267205 2,4-dihydroxybenzoic acid derivatives
12/01/2005US20050267201 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
12/01/2005US20050267200 Heteroaromate OSC inhibitors
12/01/2005US20050267190 Solid-state form of celecoxib having enhanced bioavailability
12/01/2005US20050267186 Minimal cardivascular and/or sedatory activity; treating pain and allodynia; selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors;
12/01/2005US20050267183 Selective estrogen receptor modulators
12/01/2005US20050267165 Il-8 receptor antagonists
12/01/2005US20050267163 Vanilloid receptor ligands and their use in treatments
12/01/2005US20050267126 Compounds derived from aryl carbamates, preparation thereof and uses of same
12/01/2005US20050267125 High drug load tablet
12/01/2005US20050267114 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
12/01/2005US20050267112 intravenous or oral administration; hypotensive agents; enzyme inhibitors of cGMP-metabolizing phosphodiesterases
12/01/2005US20050267044 Novel compounds and compositions as cathepsin S inhibitors
12/01/2005US20050266533 Therapeutic fusion protein with enhanced for use in prevention and treatment of cell proliferative, blood and nervous system disorders
12/01/2005US20050266532 Albumin fusion proteins
12/01/2005US20050266485 polynucleotides encoding a hematopoietic cytokine receptor polypeptide, for use in the treatment of cancer; restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer; biodrugs; test detecting a genetic disorder, cancer
12/01/2005US20050266484 gene therapy; a sequence which encodes the polypeptide podocin; proteinuria
12/01/2005US20050265976 Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells
11/2005
11/30/2005EP1600458A1 Novel gene relating to fibrotic conditions
11/30/2005EP1600163A1 Use of the neurotoxic component of botulinum toxins for the treatment of spastic muscle
11/30/2005EP1600157A1 Enteric sustained-release fine particles for tamsulosin or its salt and process for producing the same
11/30/2005EP1599482A1 Pyrazolo 1,5-a pyrimidine derivatives
11/30/2005EP1599204A2 Selective mglu5 antagonists for treatment of neuromuscular dysfunction of the lower urinary tract
11/30/2005EP1458381B1 Triazoles as oxytocin antagonists
11/30/2005EP1392337B1 Pharmaceutical formulation consisting of a plant dry extract with a calcium coating
11/30/2005EP1176981B1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/30/2005EP0888341B1 Novel sulphur derivatives comprising an amide bond, method for preparing same, use thereof as drugs, and pharmaceutical compositions containing such derivatives
11/30/2005CN1703425A Crystallization of IGF-1
11/30/2005CN1703415A Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group
11/30/2005CN1703395A Aryl and heteroaryl compounds and methods to modulate coagulation
11/30/2005CN1229351C Heterocyclic compounds and methods to treat cardiac failure and other disorders
11/30/2005CN1229349C Pyridine-3-carboxylic acid derivative
11/30/2005CN1229343C Chemotactic factor receptor active regulator
11/30/2005CN1229335C Nervinolin derivatives
11/30/2005CN1229331C Inhibitor of monoamine uptake
11/30/2005CN1229137C New therapeutic uses of SMR1 peptides
11/30/2005CN1229114C Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
11/30/2005CN1229113C A Pharmaceutical composition for the treatment of autoimmune diseases
11/29/2005US6969729 An indole or benz(g)indole-2,3-dione-3-oxime compounds; therapeutic treatment of respiratory disorders, urogenital disorders, cardiovascular disorders, brain and psychological disorders, gastrointestinal disorders
11/29/2005US6969727 Obesity; osteoporosis
11/29/2005US6969724 Compounds
11/29/2005US6969723 preferably antagonists used in the therapeutic and/or preventive treatment of disfunctions of the heart, kidney, respiratory system, central nervous system
11/29/2005US6969719 Such as 3-((3-bromo-4-hydroxyphenyl)methyl)-5-ethyl-7,8-dihydro-2-(tetrahydro-2H -pyran-4-yl)amino)-3H-imidazo(2,1-b) purin-4(5H)-one for treating sexual disorders
11/29/2005US6969718 17-β hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
11/29/2005US6969717 Azaindole kinase inhibitors
11/29/2005US6969712 Alzheimer's disease; central nervous system disorders; antidepressants; antidiabetic agents; analgesics
11/24/2005WO2005110446A1 Process to obtain extracts, fractions and isolated compounds from copaifer species and their use for the treatment of urinary lithiasis in human beings and animals
11/24/2005WO2005110427A1 Stable oral pharmaceutical preparation comprising fosfomycin, which is intended for diabetic patients
11/24/2005US20050261502 2-Amino-4-(1,3-benzodioxol-5-yl)-6-benzyloxy-3,5-pyridinedicarbonitrile, acting as adenosine-receptor-selective ligands, for the prophylaxis and/or treatment of cardiovascular disorders
11/24/2005US20050261369 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
11/24/2005US20050261349 Medicine for prevention or treatment of diabetes
11/24/2005US20050261344 Treatment of lower urinary tract symptoms associated with overactive bladder in men and women
1 ... 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 ... 562